Mainz Biomed to Host Key Opinion Leader Event at DDW 2022
May 09 2022 - 8:01AM
Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),
a molecular genetics diagnostic company specializing in the early
detection of cancer, announced today that it will bring together
key opinion leaders (KOLs) from across the Colorectal Cancer (CRC)
screening and diagnostics community in an event to be held during
Digestive Disease Week (DDW 2022) in San Diego, California.
“DDW is the center of gravity for the international digestive
disease community and an ideal forum for us to bring together a
group of leaders in their fields to discuss the future advancement
of colorectal cancer diagnostics,” commented Guido Baechler, Chief
Executive Officer of Mainz Biomed. “As a company dedicated to
developing next-generation molecular diagnostic tools to improve
early detection and prevention of CRC and other serious cancer
indications, it is invaluable to engage with industry leaders, to
share knowledge and collectively formulate ideas that have the
potential to dramatically change the lives of those living with
these diseases.”
Digestive Disease Week is the largest international gathering of
physicians, researchers and academics in the fields of
gastroenterology, hepatology, endoscopy and gastrointestinal
surgery. Jointly sponsored by the American Association for the
Study of Liver Diseases (AASLD), the American Gastroenterological
Association (AGA) Institute, the American Society for
Gastrointestinal Endoscopy (ASGE), and the Society for Surgery of
the Alimentary Tract (SSAT), DDW is an in-person and virtual
meeting, running from May 21-24, 2022. The meeting showcases more
than 5,000 abstracts and hundreds of lectures on the latest
advances in GI research, medicine, and technology.
While attending DDW 2022, Mainz Biomed CEO Guido Baechler will
also participate in the World Endoscopy Organization’s (WEO)
Colorectal Cancer Screening Committee meeting which will be held on
May 20, 2022. The committee brings together a global network of
participants with the goals to provide international fora for
topics related to colorectal cancer screening and surveillance, to
promote innovation and effective delivery of colorectal cancer
screening and surveillance, and to collaborate in addressing issues
and gaps in colorectal cancer screening and surveillance.
About ColoAlert
ColoAlert detects colorectal cancer (CRC) via a
simple-to-administer test with a sensitivity and specificity nearly
as high as the invasive colonoscopy*. The test utilizes proprietary
methods to analyze cell DNA for specific tumor markers combined
with the fecal immunochemical test (FIT) and is designed to detect
tumor DNA and CRC cases in their earliest stages. The product is
CE-IVD marked (complying with EU safety, health and environmental
requirements) and is transitioning to compliance with IVDR. The
product is commercially available in a selection of countries in
the European Union. Mainz Biomed currently distributes ColoAlert
through a number of clinical affiliates. Once approved in the U.S.,
the Company’s commercial strategy is to establish scalable
distribution through a collaborative partner program with regional
and national laboratory service providers across the country.
*Dollinger MM et al. (2018)
About Colorectal Cancer
Colorectal cancer (CRC) is the second most lethal cancer in the
U.S. and Europe, but also the most preventable with early detection
providing survival rates above 90%. Annual testing costs per
patient are minimal, especially when compared to late-stage
treatments of CRC which cost patients an average of $38,469 per
year. The American Cancer Society estimated that in 2021 there were
approximately 149,500 new cases of colon and rectal cancer in the
U.S. with 52,980 resulting in death. Recent FDA decisions suggest
that screening with stool DNA tests such as ColoAlert in the U.S.
should be conducted once every three years starting at age 45.
Currently there are 112 million Americans aged 50+, a total that is
expected to increase to 157 million within 10 years. Appropriately
testing these U.S.-based 50+ populations every three years as
prescribed equates to a U.S. market opportunity of approximately
$3.7 Billion per year.
About Mainz Biomed N.V.
Mainz Biomed develops market-ready molecular genetic diagnostic
solutions for life-threatening conditions. The Company’s flagship
product is ColoAlert, an accurate, non-invasive, and easy-to-use
early detection diagnostic test for colorectal cancer. ColoAlert is
currently marketed across Europe with FDA clinical study and
submission process intended to be launched in the first half of
2022 for U.S. regulatory approval. Mainz Biomed’s product candidate
portfolio includes PancAlert, an early-stage pancreatic cancer
screening test based on Real-Time Polymerase Chain Reaction-based
(PCR) multiplex detection of molecular-genetic biomarkers in stool
samples, and the GenoStick technology, a platform being developed
to detect pathogens on a molecular genetic basis.
For more information please visit
www.mainzbiomed.com
For media enquiries, please
contact press@mainzbiomed.com
For investor enquiries, please
contact ir@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are
“forward-looking statements” within the meaning of the “safe
harbor” provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words such as “anticipate”, “believe”, “expect”, “estimate”,
“plan”, “outlook”, and “project” and other similar expressions that
predict or indicate future events or trends or that are not
statements of historical matters. These forward-looking statements
reflect the current analysis of existing information and are
subject to various risks and uncertainties. As a result, caution
must be exercised in relying on forward-looking statements. Due to
known and unknown risks, actual results may differ materially from
the Company’s expectations or projections. The following factors,
among others, could cause actual results to differ materially from
those described in these forward-looking statements: (i) the
failure to meet projected development and related targets; (ii)
changes in applicable laws or regulations; (iii) the effect of the
COVID-19 pandemic on the Company and its current or intended
markets; and (iv) other risks and uncertainties described herein,
as well as those risks and uncertainties discussed from time to
time in other reports and other public filings with the Securities
and Exchange Commission (the “SEC”) by the Company. Additional
information concerning these and other factors that may impact the
Company’s expectations and projections can be found in its initial
filings with the SEC, including its Prospectus filed on October 12,
2021 and amended on October 25, 2021 and November 1, 2021 as well
as the Prospectus filed on January 21, 2022. The Company’s SEC
filings are available publicly on the SEC’s website at www.sec.gov.
Any forward-looking statement made by us in this press release is
based only on information currently available to Mainz Biomed and
speaks only as of the date on which it is made. Mainz Biomed
undertakes no obligation to publicly update any forward-looking
statement, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise, except as required by law.
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From Apr 2023 to Apr 2024